353 related articles for article (PubMed ID: 24283303)
21. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.
Lencioni R; Marrero J; Venook A; Ye SL; Kudo M
Int J Clin Pract; 2010 Jul; 64(8):1034-41. PubMed ID: 20642705
[TBL] [Abstract][Full Text] [Related]
22. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
[TBL] [Abstract][Full Text] [Related]
24. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
Liu F; Meng Z; Shao G; Wang J; Wang Z; Yang J; Yip CS; He D
Mol Biol Rep; 2017 Feb; 44(1):149-158. PubMed ID: 27981445
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib: A Review in Hepatocellular Carcinoma.
Keating GM
Target Oncol; 2017 Apr; 12(2):243-253. PubMed ID: 28299600
[TBL] [Abstract][Full Text] [Related]
26. [Clinic predictors of efficacy and adverse events of sorafenib therapy for advanced hepatocellular carcinoma patients].
Zhao P; Chen D; Chen W; Yin XY; Yang D; Liang LJ
Zhonghua Wai Ke Za Zhi; 2012 Jun; 50(6):514-7. PubMed ID: 22943944
[TBL] [Abstract][Full Text] [Related]
27. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
Kim HY; Park JW; Joo J; Kim H; Woo SM; Lee WJ; Kim CM
J Gastroenterol Hepatol; 2013 Nov; 28(11):1756-61. PubMed ID: 23800278
[TBL] [Abstract][Full Text] [Related]
28. Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients.
Merchante N; Ibarra S; Revollo B; Rodríguez-Arrondo F; Merino E; Delgado-Fernández M; Montero-Alonso M; Téllez F; Galindo MJ; Rivero-Juárez A; García MA; Mínguez C; Romero-Palacios A; Garcia-Deltoro M; Pineda JA;
AIDS; 2017 Jan; 31(1):89-95. PubMed ID: 27755109
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib in liver function impaired advanced hepatocellular carcinoma.
Ji YX; Zhang ZF; Lan KT; Nie KK; Geng CX; Liu SC; Zhang L; Zhuang XJ; Zou X; Sun L; Zhang ZC
Chin Med Sci J; 2014 Mar; 29(1):7-14. PubMed ID: 24698672
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
31. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
Wang W; Bai W; Wang E; Zhao Y; Liu L; Yang M; Cai H; Xia D; Zhang L; Niu J; Yin Z; Zhang Z; Fan D; Xia J; Han G
Int J Cancer; 2017 Jan; 140(2):390-399. PubMed ID: 27681592
[TBL] [Abstract][Full Text] [Related]
32. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
33. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
34. Sorafenib treatment by Child-Pugh score in Latin American patients with hepatocellular carcinoma.
de Guevara LL; Dagher L; Arruda VM; Nakajima K; Kudo M
Future Oncol; 2020 Nov; 16(31):2511-2520. PubMed ID: 32783460
[No Abstract] [Full Text] [Related]
35. On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.
Howell J; Pinato DJ; Ramaswami R; Bettinger D; Arizumi T; Ferrari C; Yen C; Gibbin A; Burlone ME; Guaschino G; Sellers L; Black J; Pirisi M; Kudo M; Thimme R; Park JW; Sharma R
Aliment Pharmacol Ther; 2017 Apr; 45(8):1146-1155. PubMed ID: 28252185
[TBL] [Abstract][Full Text] [Related]
36. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
[TBL] [Abstract][Full Text] [Related]
37. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
38. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.
Pressiani T; Boni C; Rimassa L; Labianca R; Fagiuoli S; Salvagni S; Ferrari D; Cortesi E; Porta C; Mucciarini C; Latini L; Carnaghi C; Banzi M; Fanello S; De Giorgio M; Lutman FR; Torzilli G; Tommasini MA; Ceriani R; Covini G; Tronconi MC; Giordano L; Locopo N; Naimo S; Santoro A
Ann Oncol; 2013 Feb; 24(2):406-411. PubMed ID: 23041587
[TBL] [Abstract][Full Text] [Related]
40. [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
Ikeda M; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Okuyama H; Kuwahara A; Okusaka T
Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1346-54. PubMed ID: 22863957
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
